Health & Science

Revolutionary Treatment for Lupus Sparks Hope: Katie’s Remarkable Journey to Remission

An experimental treatment that resets a malfunctioning immune system has put the disease lupus into remission in early UK trials. This groundbreaking

An experimental treatment that resets a malfunctioning immune system has put the disease lupus into remission in early UK trials. This groundbreaking approach could potentially treat similar disorders, such as multiple sclerosis and rheumatoid arthritis. Among the first patients to experience this change is Katie Tinkler, who shared that she has “never been this good” since her diagnosis 30 years ago. Once, she found it hard to walk with her children, but now she can ski and is completely off all lupus medication.

Lupus is a condition affecting approximately 50,000 people in the UK, predominantly women, who make up 90% of those diagnosed. It typically manifests in young adults and sees the immune system mistakenly attacking the body, leading to joint pain, skin conditions, and serious damage to organs like the kidneys. Katie was diagnosed in 1993 at the tender age of 20. She was determined not to let this illness dictate her life and even worked as a fitness instructor. Yet, she always kept a packet of steroids handy, just in case a flare-up struck.

When I met Katie in her vibrant kitchen in Surrey, with a glitterball whimsically hanging from the ceiling, she recounted how flare-ups in her hands would leave her struggling to lift a simple cup of tea. She needed to take medication 45 minutes before getting out of bed each morning, or else the pain would be unbearable. The past decade was particularly brutal as the disease turned more aggressive, leading Katie to endure extended hospital stays. Her condition was wreaking havoc on her heart, lungs, and kidneys, bringing her dangerously close to needing dialysis. “Lupus at its worst was in bed, unable to move, going downhill rapidly, possibly dying…now I’m living,” she told me, exuding a newfound spirit.

Fast forward to a year and a half after her experimental treatment, and Katie is bursting with energy, like a woman reborn. “It’s amazing. I’m living like a normal person, I’m literally saying yes to anything. I sort of forgot that you could feel this good,” she expressed, reveling in her newfound lease on life. The treatment she received at University College London Hospitals involved resetting her immune system by engineering a civil war within it—essentially getting one part to destroy the part that was causing her illness.

This innovative method involves two types of white blood cells—B cells and T cells. While T cells usually protect the body from infections, in lupus, B cells can go rogue and produce harmful antibodies that attack the body. Scientists took millions of Katie’s T cells and modified them in the lab, altering their targeting mechanism so they could now attack the rogue B cells. Once reintroduced into her body, these T cells destroy both the harmful and healthy B cells. But here’s the magic: after a few months, new healthy B cells grow, effectively resetting her immune system.

Katie remembers receiving a letter to her GP beforehand, stating she understood the risks and knew she might die as a result of the treatment. It was a grueling process that also involved chemotherapy to prevent her modified T cells from being rejected. She underwent the treatment in November 2024, and now she is thriving, no longer reliant on any lupus medication, with her organs having made a remarkable recovery. “I can live to an old lady with these kidneys and that is phenomenal. My heart’s much better, my lungs much better. My blood disorder is no longer there,” she declared.

Of the first six patients treated, five remain in remission, while one has shown improved symptoms but experienced a lupus flare-up after 11 months. Presenting data at the EULAR European Congress of Rheumatology, the medical team confirmed that their patients have continued to do well after more than 18 months. However, uncertainties linger over how long the treatment’s effects will last and its success in larger trials. Dr. Maria Leandro, a consultant rheumatologist at UCLH, commented to BBC News, “If we were to have patients in remission for three-to-five years consistently, that would be a major gain in lupus; it may be longer than that, but we’ll have to wait and see. This is clearly a significant step forward towards a possible cure, so it is very exciting.”

This revolutionary approach, known as CAR-T or chimeric antigen receptor T-cells, is already an approved treatment for certain blood cancers, including some leukemias and lymphomas. These early results suggest that this method may also be applicable for autoimmune diseases, many of which operate similarly to lupus. Dr. Claire Roddie, from UCL, expressed her excitement about the potential of CAR-T therapy for autoimmune diseases, mentioning conditions like multiple sclerosis and rheumatoid arthritis, which affects a vast number of patients.

Katie, although unsure how long her remission will last, is seizing every opportunity. “I want to climb mountains, I’d love to do Kilimanjaro, I’d love to do a triathlon again, I just want to participate and I want to say yes to as many things as I possibly can.” What will her next adventure be? Only time will tell…

Kaynak: Orijinal Haber

Wegovy Weight-Loss Pill Approved in the UK: What You Need to Know

A pill version of the blockbuster weight-loss drug Wegovy has been approved in the UK, meaning folks will soon be able to snag it with a prescription

A pill version of the blockbuster weight-loss drug Wegovy has been approved in the UK, meaning folks will soon be able to snag it with a prescription. This is the first tablet of its kind that has gotten the green light from the Medicines and Healthcare products Regulatory Agency (MHRA). Imagine, no more weekly injections! The manufacturer, Novo Nordisk, claims the once-a-day tablet could be a game changer for many who prefer popping a pill over jabbing themselves with GLP-1 medication that curbs appetite. Plus, these pills don’t even need to be kept in the fridge, which is a nice bonus.

Now, here’s the catch: it won’t be available on the NHS just yet. Experts need to evaluate whether it should be recommended. The National Institute for Health and Care Excellence, the body responsible for making that call, mentioned that Novo Nordisk hasn’t reached out to them yet, but they’re “in active dialogue” with the company. Meanwhile, some high street and online pharmacies are gearing up to add it to their doctor prescribing services in the coming weeks.

According to the MHRA, the starting dose for the tablet is 1.5 mg once daily, which can ramp up to 4 mg, 9 mg, and finally 25 mg, with at least a month spent on each dose level. If you’re currently on the 2.4 mg semaglutide injection weekly, you can switch directly to the 25 mg tablets taken daily. These tablets should be taken on an empty stomach and are already available across the pond in the US. Other companies are either rolling out similar products or working on their own versions.

As for the price? Well, that’s still a bit of a mystery in the UK. But when Wegovy first launched in the US, the starting dose of 1.5 mg was priced at about $149 (around £110) a month. Just like its injection counterpart, the tablets contain semaglutide, which mimics the actions of a natural hormone, GLP-1. This hormone suppresses appetite and slows down digestion, making you feel fuller for longer.

Olivier Picard, the Chair of the National Pharmacy Association, described the approval of the pill as “significant.” He noted that this could really help patients who either can’t or don’t want to take the injectable version. Plus, it might even lower the cost of treatment in the long run. “Pharmacies are waiting for further guidance on when this treatment will be available for patients,” he added.

Trials have shown that these pills are safe and effective. But, just like the injections, it might take a few months to see the full benefits. And there’s always the risk of gaining weight back after stopping the medication. It’s important for anyone taking weight-loss meds to also stick to a healthy diet and get enough exercise. These GLP-1 drugs are not intended for short-term or cosmetic weight loss, and health experts are really pushing back against using them as a quick fix for that “beach body.” Although, let’s be real, some people do misuse them.

Side effects can pop up too, including nausea, diarrhea, constipation, and vomiting. Around a third of UK adults—more than 16 million—struggle with obesity. This new approval could be a big deal for many of them.

Kaynak: Orijinal Haber

Nearly 3,000 Patients Daily Left in NHS Corridors: A Disturbing Reality

Nearly 3,000 patients a day had to be cared for in hospital corridors or makeshift treatment areas rather than in a bed on a ward in England last mon

Nearly 3,000 patients a day had to be cared for in hospital corridors or makeshift treatment areas rather than in a bed on a ward in England last month, figures show. This shocking statistic marks the first time such data has been published, revealing the immense challenge the NHS faces in addressing what ministers are calling “unsafe” and “unacceptable” conditions. This situation arises when patients are treated in makeshift areas like corridors, side-rooms, and even car parks for more than 45 minutes, or when they are left near wards without a proper bed. To put this into perspective, this daily number represents about 3-4% of patients arriving at hospitals through Accident and Emergency (A&E) departments.

Digging deeper into the numbers, the data from May indicates that an average of 2,241 patients experienced corridor care while in A&E, with an additional 669 undergoing similar treatment on or near hospital wards. It’s particularly alarming to note that 20 trusts accounted for over half of the corridor care cases in A&E, while another 20 trusts were responsible for more than two-thirds of the cases in other areas of the hospitals.

Patients and staff have shared their harrowing experiences with BBC’s Your Voice. Take Suzanne, for instance, who has taken her elderly mother to A&E in the East Midlands five times this year. Each visit meant an agonizing wait of over 24 hours in a corridor. “Mum was just one trolley in a sea of trolleys,” Suzanne recalls with a mix of frustration and sadness. Her mother, confused and distressed, only received help with basic needs like going to the toilet or getting a drink because family members were present. “If we hadn’t been there, I dread to think what might have happened…”

Kathy’s experience paints a similar picture. Sent to the hospital by her GP earlier this year with a suspected eye infection, she found herself waiting alone in a chair for a staggering 36 hours before being informed that her blurred vision was due to a brain tumor. “It was horrendous… I got home and threw up. I was exhausted and broken,” she said, capturing the emotional toll this situation has taken on patients.

Nurses, who preferred to stay anonymous, have described feelings of burnout and working under impossible conditions. One nurse recalled a shift where the corridor was packed with patients, and tragically, a body had to be wheeled past them on the way to the mortuary. Later, another patient went into cardiac arrest in that same corridor. “Those frail patients watched chest compressions. There’s no dignity in that,” she said, highlighting the grim reality of corridor care.

Another nurse likened her emergency department to a “war zone”, recounting the painful memory of witnessing a patient die unnoticed in the corridor. “He’d started to stiffen because he had been there for so long, dead, with no one noticing. It’s horrific to think someone’s loved one died with no one near them,” she lamented.

In response to this dire situation, ministers have pledged to eliminate corridor care by 2029. Health Secretary James Murray stated emphatically, “Corridor care is unacceptable, undignified, and has no place in our NHS.” He emphasized that publishing this data aims to highlight the most pressing issues and ensure that trusts receive the necessary support, particularly as the majority of corridor care is concentrated within a small number of organizations.

Despite May not being a typical month for acute pressures in hospitals, NHS England noted that the heatwave contributed to increased patient numbers. The Royal College of Nursing’s general secretary, Prof. Nicola Ranger, described the figures as “alarming,” indicating that unsafe and undignified practices are widespread. “Behind these figures aren’t just patients and families suffering, but nursing staff demoralized at being forced to deliver poor care, day in and day out,” she remarked.

Siva Anandaciva from The King’s Fund health think tank also weighed in, stating, “These figures confirm the scale of something that should never have been normalized in the NHS.” While he acknowledged it was a “positive step” to have the figures publicly available, he cautioned, “We have had data on long waits in other parts of the NHS for decades – including A&E departments – and it has done little to stop their rise.”

Bakalım bu durum daha ne kadar devam edecek? Gelişmeleri takip ediyoruz…

Kaynak: Orijinal Haber

New Hope for Ozempic Users: Apitegromab to Combat Muscle Loss!

A new drug called apitegromab could help folks on obesity jabs avoid that dreaded muscle decline that’s been linked to flat bums or the notorious

A new drug called apitegromab could help folks on obesity jabs avoid that dreaded muscle decline that’s been linked to flat bums or the notorious “Ozempic butt.” This revelation comes from research published in the Nature Medicine journal, suggesting that about a third of the weight loss from GLP-1 obesity medications like Wegovy and Mounjaro can come from muscle instead of fat. In a trial involving 102 adults, mostly women, it was found that those who took apitegromab alongside their obesity meds managed to keep more muscle while still shedding fat, as shown by body scans. But, hold on a minute—experts stress that more evaluation studies are needed before giving this the green light.

Now, let’s break it down a bit more. People using GLP-1 drugs like Ozempic, Wegovy, and Mounjaro often experience an exaggerated loss of fat, muscle, and tissue volume as the pounds drop off quickly. This isn’t just a side effect of the medication itself, but rather a consequence of rapid weight loss. These jabs work by curbing appetite and making you feel fuller for longer, which means you end up eating way less and losing weight. But here’s the kicker: unlike fat, it’s a whole lot tougher to rebuild muscle fast. Some users have even expressed concerns about their body shape changing—yep, that deflated or saggy bum look has been dubbed the “Ozempic butt.” And guess what? U.S. plastic surgeons are noticing a “noticeable uptick” in consultations about this very issue. Can you believe that?

People on GLP-1s are already advised to adopt a healthy diet and engage in exercise, including strength training, to maintain their muscle mass. It’s crucial to note that GLP-1 drugs aren’t designed for quick fixes or cosmetic weight loss, and health experts are ringing the alarm against using them as a shortcut to get that “beach body” ready, even though it’s clear some people misuse them. Right now, apitegromab is only available for clinical trials and has to be administered via an infusion. The company behind it, which funded the research, is looking into whether folks could self-inject it with a special pen—just like those GLP-1 jabs.

So, how does apitegromab work? It blocks a protein involved in muscle breakdown and is also being explored as a treatment for other muscle-related medical conditions, including spinal muscular atrophy. In the six-month obesity trial that utilized the weight-loss drug Mounjaro, participants who also received apitegromab retained around 1.9 kg or 55% more muscle, also known as ‘lean mass’. To put it in perspective, lean mass constituted 14.6% of total weight loss in the apitegromab group, compared to a whopping 30.2% in the placebo group that received a dummy treatment alongside Mounjaro. Dr. Marie Spreckley from Cambridge University, who wasn’t involved in the research, pointed out that while the findings seem promising, they should be viewed as “encouraging early evidence” rather than definitive proof of clinical benefits. She’s calling for larger, longer studies to see if preserving muscle can indeed boost strength, wellbeing, and long-term health outcomes.

Dr. Brendan Gabriel, a nutrition and health expert at the University of Aberdeen, mentioned that this treatment might not be suitable for everyone on GLP-1 drugs but could potentially assist those losing muscle mass rapidly. And here’s a tip: you don’t need a gym to do strength training. Any activity that makes your muscles work harder counts! This helps increase your muscles’ strength, size, power, and endurance. The NHS recommends starting small and building up, aiming for at least two sessions a week. And let’s not forget about diet; getting enough protein is vital. Research suggests that consuming 20-40g of protein per meal can help maintain or build muscle mass. A good rule of thumb? Fill a quarter of your plate with protein-rich foods like meat, fish, beans, lentils, or chickpeas at every meal. Protein-rich snacks? Think yoghurts, boiled eggs, and nuts.

This whole situation is definitely evolving, and as we learn more about apitegromab and its effects, the future looks intriguing. What’s next for those navigating the challenges of weight loss and muscle maintenance? We’re all ears for the upcoming developments!

Kaynak: Orijinal Haber

Revolutionary New Radiotherapy Slashes Prostate Cancer Treatment Sessions from 20 to 5!

Thousands of men in England with prostate cancer are set to benefit from a groundbreaking treatment that will dramatically reduce their radiotherapy

Thousands of men in England with prostate cancer are set to benefit from a groundbreaking treatment that will dramatically reduce their radiotherapy sessions from the usual 20 down to just five. This new approach, known as SABR (stereotactic ablative radiotherapy), is poised to deliver a more focused and effective attack on the cancer, while also minimizing the side effects that often come with traditional radiotherapy.

This is the first time that this advanced technique will be made available to low- and intermediate-risk prostate cancer patients outside of clinical trials. Each year, around 55,000 men in the UK are diagnosed with prostate cancer, with about 17,500 classified as low or intermediate risk. Experts predict that approximately 3,500 of these men might opt for this innovative treatment, particularly since many low-risk patients choose active monitoring instead of immediate intervention due to the typically slow-growing nature of their cancers.

NHS England has announced that all 48 radiotherapy centers across the country are expected to start offering this treatment “within weeks,” which is great news for those affected. Professor Peter Johnson, the national clinical director for cancer, underlined the significance of this advancement, stating that it allows for a highly concentrated beam of radiotherapy to be aimed directly at the cancer, thus limiting damage to surrounding healthy cells. He emphasized that undergoing this treatment in just five sessions, rather than the usual 20, means men can get back to their normal lives much more quickly.

Amy Rylance from Prostate Cancer UK expressed her enthusiasm, calling it “wonderful news” that thousands of men will now have access to this revolutionary targeted therapy. She highlighted that this could significantly ease the burdens faced by these men and their families. The charity is also hopeful that further advancements will allow even more prostate cancer patients to benefit from this treatment.

Trials are already in progress to investigate whether this precision radiotherapy can also be extended to high-risk prostate cancer patients. Edwin Lambert, a 70-year-old man from Suffolk, is participating in one of these trials. Diagnosed with prostate cancer in January 2025, he began hormone therapy but faced challenging side effects, including mood swings and fatigue. After receiving SABR, he reported that the treatment was “easier to deal with” compared to traditional options. While undergoing treatment, he observed other patients receiving standard radiotherapy who looked “dreadful” due to repeated sessions. Edwin experienced some discomfort, such as frequent urination during and shortly after his sessions, but was back to his archaeological dig within five weeks, describing the treatment as an “absolute godsend.”

In related news, a local charity event called Dorset’s Distinguished Gentleman’s Ride has raised more funds for cancer than any other event in Europe. Kevin Webber, who has been fundraising since his diagnosis in 2014, has clocked over 20,000 miles in support of cancer research. Meanwhile, health experts are still evaluating the best ways to screen for prostate cancer, as blood tests alone lack the necessary accuracy for many men.

With the ongoing developments in prostate cancer treatment, it’s clear that hope is on the horizon for many. As the healthcare community continues to explore new avenues, one can’t help but wonder what other breakthroughs are yet to come…

Kaynak: Orijinal Haber

Christian Eriksen’in Kalp Cihazı Hayat Kurtardı: Olay Anı ve Sonrası

Footballer Christian Eriksen says he is “doing well” at home with his family and has already started his recovery, after collapsing during an interna

Footballer Christian Eriksen says he is “doing well” at home with his family and has already started his recovery, after collapsing during an international match between Denmark and Ukraine on Sunday. The 34-year-old Dane, whose heart stopped following a cardiac arrest five years ago, was able to walk off the pitch after regaining consciousness – thanks to a tiny device implanted in his chest, called an ICD (implantable cardioverter defibrillator). On social media, Eriksen posted: “My ICD did exactly what it was designed to do: protect me when I needed it.”

Yaşanan olay, futbol dünyasında şok etkisi yarattı. Eriksen, daha önce de benzer bir durumla karşılaşmıştı. Hatırlarsanız, 2021 yılında Avrupa Şampiyonası sırasında kalp krizi geçirip bayılmıştı. O zaman da futbol sahasında hemen müdahale edilmişti. Yani, bu olayın ne kadar ciddi olduğunu bir düşünün… Şimdi ise, bu minik cihaz sayesinde hayatı kurtuldu. Bu ICD, kalbin ritminde bir sorun tespit ettiğinde hemen devreye giriyor ve düzeltme yapıyor. Yani, tam anlamıyla hayati bir rol üstleniyor.

Cihaz iki ana türde mevcut. Birincisi, deri altına yerleştiriliyor ve mini bir defibrilatör gibi çalışıyor. Genellikle koltuk altına yakın bir yerde yer alıyor. Diğeri ise doğrudan kalbe bağlı ve kalbin yavaşladığı durumlarda elektrik sinyalleri gönderiyor. Eriksen’in durumunda, cihaz muhtemelen kalp atışlarının tehlikeli derecede hızlı veya anormal olduğunu tespit etti ve ona bir elektrik şoku göndererek kalbinin normal ritmine dönmesine yardımcı oldu. Prof. Aneil Malhotra, Manchester Metropolitan Üniversitesi’nden spor kardiyologu, bu durumu “kalbi yeniden başlatmak” olarak tanımlıyor. “Bir bilgisayarı açıp kapatmak gibi,” diyor.

Eriksen’in yaşadığı bu ikinci çöküş, genç yaşta kalp sorunlarının ne kadar ciddi sonuçlar doğurabileceğini gözler önüne serdi. Yani, bu durum sadece bir futbolcu için değil, gençler için de büyük bir tehdit oluşturuyor. Birleşik Krallık’ta, 35 yaş altındaki her hafta 12 kişi ani kalp durmasından hayatını kaybediyor. Dr. Steve Cox, bu tür durumların sık meydana geldiğini ve çoğu zaman herhangi bir belirti olmadan gerçekleştiğini vurguluyor.

Futbol dünyasında, Eriksen gibi sporcular için kalp taramaları artık standart hale geldi. İngiltere’deki 92 Premier ve Futbol Ligi kulüpleri, ilk profesyonel sözleşmelerini imzaladıklarında ve 18 ile 20 yaşlarında kalp taramasından geçiyorlar. Bu, kalp sağlığını kontrol etmek için önemli bir adım.
Hadi bakalım, bu olaydan sonra Eriksen’in futbol kariyeri nasıl şekillenecek? İlerleyen günlerde bu konudaki gelişmeleri hep birlikte göreceğiz…

Kaynak: Orijinal Haber

New Study Reveals Top Five Foods for a Healthy Heart!

Eating specific types of fresh food daily, rather than just any five portions of fruit and vegetables, can significantly contribute to keeping your h

Eating specific types of fresh food daily, rather than just any five portions of fruit and vegetables, can significantly contribute to keeping your heart in top shape, according to a new study. Researchers suggest that not all five-a-day recommendations are created equal, as many folks might be missing out on critical nutrients known as flavanols that are essential for heart health. Blueberries, plums, blackberries, broad beans, and cherries—when paired with green tea—are touted as the best options to boost your flavanol intake.

In a comprehensive study involving 30,000 participants from both the US and the UK, it was found that even those who regularly consumed five portions of fruits and vegetables often lacked these vital nutrients. Can you believe it? Other experts, however, urge caution, pointing out that it’s still unclear whether increasing flavanol levels will actually prevent heart problems. It was highlighted in the journal Food and Function that less than one in five individuals manage to get the recommended daily intake of flavanols, which is around 500mg. These antioxidants, found in particular foods, can enhance heart health by improving circulation and blood vessel elasticity while reducing inflammation.

The research meticulously tracked participants’ diets and monitored flavanol intake using biomarkers in their urine. Dr. Javier Ottaviani, the lead investigator, emphasized that even simple food swaps could lead to significant improvements in how much of these beneficial compounds are absorbed. “Most people think loading up on fruits and vegetables is enough, but this research clearly shows that the specific choices you make are far more important than just the total amount consumed,” he said.

Prof. Gunter Kuhnle from the University of Reading echoed this sentiment, stating that while the five-a-day message is still vital, we need to be more discerning about which five we choose. He noted, “Different fruits and vegetables provide a variety of nutritional benefits beyond just vitamins and minerals.” As our understanding of these compounds deepens, there’s a real chance to refine dietary guidance to be more specific and effective.

The NHS has yet to set a recommended daily flavanol level, but experts from the US Academy of Nutrition and Dietetics suggest that around 500mg a day is beneficial for heart health. Based on this study, foods with the highest flavanol content per serving include the aforementioned fruits and even dark chocolate. Speaking of chocolate, researchers have been collaborating with Mars Inc. to explore cocoa flavanol supplements. But here’s the kicker—the actual flavanol content in commercial chocolate varies widely. Dark chocolate is often viewed as the healthier option over milk chocolate due to its lower sugar and higher cocoa content, which is rich in flavanols. A couple of squares of dark chocolate could pack between 22-73mg of flavanols, while a few pieces of milk chocolate might only provide 3-7mg.

Heart specialist Prof. Naveed Sattar from the University of Glasgow warned that although some small trials have shown favorable effects of flavonoids on blood pressure, there’s still no solid evidence proving that they can reduce heart disease outcomes. More extensive trials are necessary before these compounds can be confidently recommended as a preventive measure against cardiovascular events like heart attacks and strokes.

Prof. Ana Rodriguez-Mateos, a nutrition expert at King’s College London, noted that the flavanol levels in fruits and vegetables can vary significantly, just like their fiber content, and this warrants further investigation. Additionally, Dell Stanford from the British Heart Foundation pointed out that the flavanol content in different foods can depend on various factors such as where they are grown, the climate, their ripeness, and how they are processed. “Small amounts are absorbed directly, and our gut bacteria help break down flavanols into usable forms, but since everyone’s gut bacteria differ, the benefits may vary from person to person,” he explained.

Both the BHF and the British Nutrition Foundation emphasize that the best way to support heart health is to adhere to established advice of consuming a balanced diet rich in a variety of fruits and vegetables. So, what do you think about these findings? Could our daily fruit and veggie intake be missing the mark?

Kaynak: Orijinal Haber

Revolutionary AI-Designed Vaccine Could Change Pandemic Preparedness Forever!

Researchers at the University of Cambridge have made a groundbreaking announcement: they’ve developed a vaccine designed entirely by artificial in

Researchers at the University of Cambridge have made a groundbreaking announcement: they’ve developed a vaccine designed entirely by artificial intelligence, and it’s being hailed as a “fundamentally new” type of vaccine. This innovative jab could potentially protect against a wide range of viruses, making it a crucial tool in preventing future pandemics. The excitement in the air is palpable as this is the first time that a vaccine’s key component has been fully crafted through AI technology and subsequently trialed in humans.

So, what makes this vaccine so special? Well, it’s engineered to combat all coronaviruses, which means it covers every variant of Covid we’ve seen so far, plus those pesky viruses that currently jump between animals and humans and could spark the next global health crisis. Hold on to your hats, folks, because while this research is still in its infancy, the Cambridge team is already working on separate vaccines targeting flu and Ebola too.

Vaccines, as we know, teach our bodies to recognize and fend off infections. But here’s the kicker: some viruses are masters at changing their appearance, like chameleons, which means our vaccines can quickly become outdated. This is exactly why we need to regularly update Covid and winter flu vaccines. As Prof. Jonathan Heeney from the University of Cambridge puts it, “We’re always behind.” But now, they’re aiming to get ahead of the curve – so far ahead that they might even protect us from new outbreaks or pandemics before they arise.

Traditionally, vaccine development relies on existing strains of viruses, but the clever folks at Cambridge took a different route. They analyzed genetic codes from various coronaviruses, collected through surveillance programs that monitor potential viral threats. These codes were then fed into an AI system, which created a “super-antigen.” This isn’t just any antigen; it’s designed to train our immune systems to recognize and attack the entire family of coronaviruses, even those that might mutate or jump from animals to humans. How cool is that? Antigens are the heart of vaccines, the very elements our immune systems learn to target.

Prof. Heeney emphasizes that this is the first instance of an AI-designed antigen being trialed on humans, and the results are nothing short of astonishing. He noted, “This technology is surprising all of us,” adding that it’s “amazing what we can do with it for the good of humanity.” He further explained that these vaccines aim to shield us not just from today’s viruses but from future outbreaks and diseases. This approach represents a significant shift in how we prepare for pandemics.

The initial trials involved 39 participants, primarily focused on assessing the safety of this new vaccine. A more extensive second study, which will include around 200 individuals, aims to provide deeper insights into how effectively this vaccine trains the immune system. The results published in the Journal of Infection indicate that the immune response generated was “modest,” but the excitement surrounding these early findings is undeniable.

Prof. Saul Faust, who conducted some of the trials at the University of Southampton, expressed optimism about the AI design. He stated that it “definitely has potential” and remarked on its capacity to adapt to the ever-changing landscape of potential pandemics. The Cambridge team isn’t stopping here; they’re already conducting animal research on universal seasonal flu vaccines that wouldn’t require yearly tweaks, along with an H5N1 bird flu vaccine, just in case the current crisis affecting birds turns into a human pandemic. And let’s not forget about viral hemorrhagic fevers, including Ebola, especially with the ongoing outbreak in the Democratic Republic of Congo, which involves a strain lacking a developed vaccine.

Prof. Andy Pollard, director of the Oxford Vaccine Group and not directly involved in the study, shared that this innovative approach is generating compelling evidence in animal research. He called the data “fascinating,” noting that such immune responses were unexpected. However, he cautioned that the real test lies ahead in human trials, given the differences between our immune systems and those of laboratory mice, which have been shaped by years of infections.

Looking ahead, the role of artificial intelligence in vaccine research is poised to be a “game changer.” AI tools have the potential to predict how our immune systems will respond to vaccines, significantly speeding up the development process and ultimately saving lives. Prof. Marian Knight, scientific director for the National Institute for Health and Care Research, highlighted that the success of this AI-designed “super-antigen” trial marks a pivotal leap forward in providing broad, lasting viral protection.

Science Minister Lord Vallance chimed in, celebrating yet another British scientific success story. He pointed out that this is a prime example of how our research expertise, combined with AI, can lead to new treatment options. With the first human trials showing promising results, this could indeed expedite vaccine rollouts, benefitting people globally in the long term. So, what’s next for this revolutionary vaccine? We’ll be keeping a keen eye on future developments…

Kaynak: Orijinal Haber

One in Four Births in England Now Emergency Caesarean, Alarming Rise Revealed

A quarter of all babies born in England are now arriving into the world via emergency caesarean sections, according to a recent analysis by the BBC.

A quarter of all babies born in England are now arriving into the world via emergency caesarean sections, according to a recent analysis by the BBC. This marks a staggering increase over the last five years, with unplanned surgeries climbing by eight percentage points. Meanwhile, the rate of vaginal births without the aid of instruments has significantly dropped, plummeting from over half of all deliveries to just 43%. It seems like a total transformation in the way women give birth in England, a change that the director of the National Perinatal Epidemiology Unit, Prof Marian Knight, believes is unprecedented compared to other European countries.

But here’s the kicker: The NHS doesn’t release data on why these emergency C-sections are happening, which leaves experts scratching their heads over the reasons behind this surge. Some insiders worry that a growing culture of fear in maternity wards, both among medical staff and expectant mothers, is pushing the number of emergency procedures higher. The Royal College of Obstetricians and Gynaecologists has noted that the strain on healthcare staff and surgical facilities has left the system gasping for air, struggling to keep up with the mounting demand for these operations. NHS England insists that decisions are made based on individual circumstances and clinical guidance to ensure the safest birthing method for both mothers and babies.

So what’s the deal with these emergency C-sections? They can range from life-threatening situations for either the mother or her baby to instances where labor isn’t progressing as it should. BBC Verify has been on the case, tracking birth trends and revealing that while vaginal deliveries remain the most common method, their prevalence has seen a noticeable drop—from 53% to 43%. As for planned caesareans, they now account for 20% of births, while emergency C-sections have seen a steady rise, soaring from 18% to 26%.

And it’s not just England that’s affected. Emergency C-section rates in Scotland are at 22%, 20% in Wales, and 16% in Northern Ireland. In a comparative study of 42 countries, Prof. Knight’s unit found that England has jumped from 14th to 9th in terms of C-section rates in just five years, while most other countries aren’t experiencing such steep increases. Despite this troubling trend, the rates of stillbirths and neonatal deaths have remained relatively stable.

Prof. Shakila Thangaratinam from the University of Liverpool has raised concerns about this increase, especially since it hasn’t been accompanied by a decrease in stillbirths or maternal complications. She pointed out that the reasons for this spike are largely unknown, emphasizing the need for better data reporting to understand the situation fully. Interestingly, she also wants to look into how race plays a role in this phenomenon. While the national average for emergency C-sections is one in four births, that figure rises to about one in three for black and Asian mothers.

As if that wasn’t complicated enough, Prof. Knight believes factors such as age, obesity, and pre-existing health issues might be driving the increase as well. But let’s not forget the huge impact of recent maternity scandals that have left many healthcare workers—and mothers—feeling anxious. For years, the norm was to keep C-section rates low, but those targets were scrapped in 2022. With reports of tragic outcomes in cases from Morecambe Bay to East Kent, ongoing investigations in Nottingham and Leeds are also raising alarms.

Prof. Knight highlights that the fear among women, families, and staff could be influencing the decision to choose or recommend C-sections more often. One healthcare professional candidly remarked that nobody wants to be involved in the next scandal. Legal claims against the NHS for maternity-related issues have risen by 11% over the past five years, often questioning why a C-section wasn’t performed or wasn’t conducted sooner. It’s worth noting that doctors and midwives rarely face criticism for opting for an early C-section.

At Northwick Park Hospital in London, the BBC spent two days observing the maternity unit and met Khushi, an 18-year-old new mother who underwent an emergency C-section because her baby’s heart rate kept dipping during labor, classifying it as category one—the most urgent kind. She expressed her feelings of confusion and fear, recalling that she had no idea what she was getting into. “It was my first ever surgery. Just the thought of being open on a table still feels so surreal and so unbelievable,” she said. Now, at home with her baby, Aarav, she faces a six-week recovery from major surgery, but she insists the mental trauma is even tougher to cope with.

Dr. Alison Wright, the president of the Royal College of Obstetricians and Gynaecologists, has been delivering babies for 35 years and is deeply concerned about how services will adapt to accommodate the rising number of emergency C-sections. Many maternity units are already stretched thin when it comes to dedicated obstetric theaters. “If we don’t invest in our workforce and in our operating theater capacity, we may find ourselves in a situation where we can’t perform the emergency caesareans we desperately need,” she stated.

According to health economist Prof. Ed Wilson from the University of Exeter, the financial implications are significant as well. A routine vaginal delivery can cost nearly £4,800, while a planned caesarean runs about £6,000. But emergency C-sections? Those can skyrocket to nearly £9,000. An NHS spokesperson has reiterated that the rise in emergency C-sections is influenced by numerous factors, but maintaining the safety and wellbeing of mothers and babies is always their top priority.

The Department of Health and Social Care has committed to enhancing maternity and neonatal safety, with Health Secretary James Murray leading a national maternity task force. Meanwhile, the community is left hoping that these ongoing reviews and investigations will lead to real improvements in maternity care.

Kaynak: Orijinal Haber

New Ovarian Cancer Drug Mirvetuximab Offers Hope for Patients

A breakthrough drug for ovarian cancer that is kinder on the body and extends lives is now available on the NHS. This revolutionary treatment, known

A breakthrough drug for ovarian cancer that is kinder on the body and extends lives is now available on the NHS. This revolutionary treatment, known as mirvetuximab soravtansine, is often referred to as a “biological missile.” Why? Because it delivers chemotherapy drugs directly to the cancerous tissue, sparing the rest of the body from the harsh side effects usually associated with traditional chemotherapy. Imagine being able to visit family, enjoy a night out at the theatre, or simply live life to the fullest again—this is the promise that mirvetuximab brings to patients like Patricia Hill.

Patricia, a 64-year-old from north London, was diagnosed with ovarian cancer in 2023 and endured multiple rounds of chemotherapy that left her feeling exhausted and ill. Fast forward to January this year, when she began treatment with mirvetuximab. The transformation she experienced was staggering. “The difference was like night and day,” she says, visibly moved. This new therapy has given her “a lot of my life back.” Now she’s able to enjoy outings to the West End, dine at her favorite restaurants, and even attend the Chelsea Flower Show. “It actually opens up a lot of possibilities,” she adds, beaming with hope.

The statistics are equally compelling. Up to 400 patients a year in England could benefit from mirvetuximab, marking the first new treatment for hard-to-treat ovarian cancer in two decades. In the UK, nearly 7,750 cases of ovarian cancer are reported annually. The treatment not only extends life—averaging 16.5 months compared to 12.8 months on traditional chemotherapy—but crucially enhances the quality of life. Patients can keep their hair, experience fewer side effects, and receive treatment via drip every three weeks rather than a weekly regimen.

Mirvetuximab works by targeting specific markers on cancer cells, known as folate receptor alpha. These markers allow the drug to home in on cancer cells, deliver a potent dose of chemotherapy exactly where it’s needed, and then release its toxic payload to destroy the cancer. It’s often described as a “Trojan horse” therapy, reminiscent of the Greek myth, because it cleverly disguises itself to reach its target.

Jenny Green, a 71-year-old from Hertfordshire, was part of the clinical trials that confirmed the drug’s effectiveness. Diagnosed in 2017, she reports, “I seem to have tolerated it very well, with hardly any side effects at all.” Her recent scan showed that her cancer nodules were shrinking, and her blood levels were returning to normal—encouraging news for anyone facing such a daunting diagnosis.

Dr. Rowan Miller, who spearheaded the clinical trials at UCLH, expressed her excitement about the drug’s approval by the National Institute for Health and Care Excellence (NICE). “Finally, there’s a drug that’s available that improves survival for this group of patients and in addition, patients find it easier to manage than standard chemotherapy,” she shared. This is a sentiment echoed by Professor Ruth Plummer, NHS national clinical lead for cancer drugs, who hailed it as the “most significant breakthrough” in treating these challenging ovarian cancers in over two decades.

The NHS has committed to funding this life-changing drug, and while Wales and Northern Ireland typically follow similar guidelines, Scotland has its own decision-making process. Victoria Clare, chief executive officer at Ovacome, a UK ovarian cancer support charity, expressed her delight, stating, “This decision has the potential to make a real difference to those who are able to access this treatment.”

Mirvetuximab soravtansine was developed by AbbVie, and its availability on the NHS marks a crucial moment for women battling platinum-resistant ovarian cancer and their families, who have long faced limited treatment options.

So, what’s next for patients and healthcare providers? Will this landmark treatment pave the way for even more advancements in cancer care? Only time will tell, but the hope it brings is undeniable…

Kaynak: Orijinal Haber